Who Can Participate?
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Phase 1b Clinical Trial of D2C7-IT + 2141-V11 combination immunotherapy administered via convection enhanced delivery in non-enhancing tumor post-resection of recurrent glioblastoma, followed by cervical perilymphatic subcutaneous injections of 2141-V11
Principal Investigator
Annick
Desjardins
Protocol Number
PRO00115800
NCT ID
NCT06455605
Phase
I
Enrollment Status
Open to Enrollment